Abstract: Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors, virions thereof, compositions and vaccines comprising such, and methods of use thereof are each provided.
Type:
Grant
Filed:
June 1, 2018
Date of Patent:
August 27, 2019
Assignee:
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Inventors:
William Jacobs, Jr., Pablo A. Gonzalez-Munoz, Betsy Herold, Christopher Petro
Abstract: The present invention addresses a need for antibodies useful for filovirus infections.
Type:
Application
Filed:
September 18, 2018
Publication date:
June 20, 2019
Applicants:
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC., THE GOVERNING COUNCEL OF THE UNIVERSITY OF TORONTO, THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE ARMY
Inventors:
Jonathan R. Lai, Jayne F. Koellhoffer, Julia Frei, Kartik Chandran, Sachdev Sidhu, Gang Chen, John M. Dye, Samantha Zak
Abstract: Synthetic fragment antigen-binding (Fab) antibodies are disclosed that bind to an N-terminal activation site of BCL-2-associated X-protein (BAX) and inhibit BAX activation. Also disclosed are methods of using the Fabs for measuring inactive monomeric BAX levels, screening for small molecules that bind to an N-terminal activation site of BAX, inhibiting apoptotic cell death, and predicting the ability of a cancer therapy to promote apoptotic cell death.
Type:
Application
Filed:
January 30, 2019
Publication date:
May 30, 2019
Applicants:
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC., THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO
Inventors:
Evripidis Gavathiotis, Jonathan R. Lai, Sachdev Sidhu
Abstract: The present disclosure provides variant PD-L1 immunomodulatory polypeptides, and fusion polypeptides comprising the variant immunomodulatory peptides. The present disclosure provides T-cell modulatory multimeric polypeptides, and compositions comprising same, where the T-cell modulatory multimeric polypeptides comprise a variant immunomodulatory polypeptide of the present disclosure. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the T-cell modulatory multimeric polypeptides, and host cells comprising the nucleic acids. The present disclosure provides methods of modulating the activity of a T cell; the methods comprise contacting the T cell with a T-cell modulatory multimeric polypeptide of the present disclosure.
Type:
Application
Filed:
May 17, 2017
Publication date:
May 23, 2019
Applicant:
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Inventors:
Sarah C. Garrett-Thomson, Steven C. Almo, Ronald D. Seidel III
Abstract: Fungal infections are difficult to diagnose. The most common filamentous fungal infection, aspergillosis, carries with it a high mortality. Culture of the organism is difficult and obtaining samples, e.g., though a lung biopsy, sometimes causes morbidity. Biomarkers that indicate ‘early’ infection in it development are sought after. One such biomarker is detection of galactomannan (GM), a polysaccharide that is attached to hyphal cell walls and secreted during growth of the organism. Galactomannan is excreted in urine. Disclosed herein is a lateral flow assay comprising monoclonal antibodies that recognize specific residues of Aspergillus fumigates for detecting GM in urine samples to provide a point-of-care detection device to allow for frequent screening and early diagnosis in patients at high risk for infection.
Type:
Grant
Filed:
November 23, 2010
Date of Patent:
May 14, 2019
Assignees:
The Johns Hopkins University, Albert Einstein College of Medicine, Inc.
Inventors:
Kieren A. Marr, Janet F. Staab, Marta Feldmesser
Abstract: Isolated polypeptides comprising engineered mutant PD-1 polypeptide are provided, as are fusion polypeptides comprising the mutant and methods of use thereof. Bispecific PD-L1 and PD-L2 binding mutant PD-1 polypeptides are provided. PD-L2-specific binding mutant PD-1 polypeptides are also provided.
Type:
Application
Filed:
May 9, 2017
Publication date:
May 2, 2019
Applicant:
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Inventors:
Jonathan R. Lai, Steven Almo, Nina Liu, Julia Frei
Abstract: Methods are disclosed for treating cancers using antibodies and antibody fragments that inhibit the activity of Vascular cell adhesion molecule 1 (Vcam1) and/or Macrophage erythroblast attacher (Maea).
Type:
Application
Filed:
November 26, 2018
Publication date:
March 14, 2019
Applicant:
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Inventors:
PAUL S. FRENETTE, SANDRA PINHO, QIAOZHI WEI
Abstract: Methods of treating a wound in a subject are provided comprising administering to the subject an amount of an inhibitor of Fidgetin-like 2. Compositions and pharmaceutical compositions comprising an amount of an inhibitor of Fidgetin-like 2 are also provided. Methods are also provided for identifying an inhibitor of Fidgetin-like 2.
Type:
Grant
Filed:
March 12, 2018
Date of Patent:
March 5, 2019
Assignee:
Albert Einstein College of Medicine, Inc.
Abstract: Methods and systems for obtaining inhibitors of Nuclear receptor SET Domain containing protein 2 (NSD2) are disclosed where the methods involve designing compounds that resemble the NSD2 transition state.
Type:
Application
Filed:
December 14, 2016
Publication date:
January 24, 2019
Applicant:
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Abstract: Methods of treating infections due to Helicobacter pylori (H. pylori), in particular in subjects having a peptic ulcer, are disclosed where the methods comprise administering inhibitors of H. pylori MTAN (5?-methylthioadenosine nucleosidase) to the subject.
Type:
Application
Filed:
September 20, 2018
Publication date:
January 17, 2019
Applicants:
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC., VICTORIA LINK LIMITED
Inventors:
Vern L. Schramm, Keith Clinch, Shivali Ashwin Gulab
Abstract: Methods and compositions are provided for inhibiting or treating metastasis based on discoveries regarding Kifl9 and Cep192. Methods and compositions are provided for enhancing wound healing, treating fibrosis, reducing scarring and treating nerve pain.
Type:
Application
Filed:
September 27, 2018
Publication date:
January 17, 2019
Applicant:
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Abstract: Methods and products are provided for determining if a subject having a tumor is at risk of metastasis of the tumor. Specifically, the methods comprise detecting phosphorylated cofilin, and both phosphorylated and non-phosphorylated cofilin; quantifying the phosphorylated cofilin, and the total of phosphorylated and nonphosphorylated cofilin; and determining if a subject having the tumor is likely to experience metastasis of the tumor, based on the ratio of the amount of detected phosphorylated cofilin:total amount of phosphorylated and non-phosphorylated cofilin detected. Further disclosed are the types of tumor metastases that can be determined using the methods provided.
Type:
Application
Filed:
July 24, 2018
Publication date:
January 10, 2019
Applicants:
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC., KING'S COLLEGE LONDON
Inventors:
John Condeelis, Tony Tsz-Cheong Ng, Gregory Weitsman
Abstract: A novel optogenetic system, including constructs and methods, is provided based on the interaction of Rhodopseudomonas palustris BphP1 and Rhodopseudomonas palustris PpsR2 or a non-dimerizing variant thereof.
Type:
Application
Filed:
September 29, 2016
Publication date:
December 6, 2018
Applicant:
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Inventors:
Vladislav V. Verkhusha, Andrii A. Kaberniuk, Anton A. Shemetov
Abstract: Methods and formulations are provided for treating or preventing arthritis, in particular osteoarthritis, where the formulation to be administered to a subject for treating or preventing arthritis comprises carvacrol, curcumin, epigallocatechin-3-gallate and oligomeric procyanidins. The invention provides methods of treating or preventing arthritis, such as osteoarthritis, in a subject in need thereof comprising administering to the subject a formulation or composition comprising carvacrol, curcumin, epigallocatechin-3-gallate and oligomeric procyanidins in an amount effective to treat or prevent arthritis.
Type:
Application
Filed:
November 2, 2015
Publication date:
November 22, 2018
Applicants:
Montefiore Medical Center, Albert Einstein College of Medicine, Inc.
Inventors:
Hui B. Sun, Daniel J. Leong, Neil J. Corbelli, David M. Hirsh, John A. Hardin, Karen E. Sperling, Sun Jin Kim, David C. Spray, Chandan Guha, Marwa Choudhury
Abstract: Methods of treating infections due to Helicobacter pylori (H. pylori), in particular in subjects having a peptic ulcer, are disclosed where the methods comprise administering inhibitors of H.
Type:
Grant
Filed:
February 6, 2015
Date of Patent:
November 6, 2018
Assignees:
Albert Einstein College of Medicine, Inc., Victoria Link Limited
Inventors:
Vern L. Schramm, Keith Clinch, Shivali Ashwin Gulab
Abstract: A microfluidic intravital window includes an intravital imaging window adapted for implantation adjacent target tissue of a live animal, and a microfluidic fluid source and delivery system physically integrated into the window for controlled delivery of fluids to target tissue via the window. The microfluidic fluid source and delivery system is self-contained and completely located within the intravital imaging window, and includes at least one preloaded fluid reservoir, at least one fluid port in fluidic communication with both the at least one preloaded fluid reservoir and the target tissue, and at least one light activated fluid flow control device situated between the at least one preloaded fluid reservoir and at least one fluid port, to facilitate simultaneous in vivo viewing and remotely controlled fluid delivery to the target tissue.
Type:
Grant
Filed:
December 7, 2016
Date of Patent:
November 6, 2018
Assignees:
The Research Foundation for the State University of New York, Albert Einstein College of Medicine, Inc.
Inventors:
James Castracane, Logan Butt, David Entenberg, Lauren Sfakis, John Condeelis
Abstract: The invention is directed to compositions and methods related to proteins that are physically associated with ceramide-like glycolipids for use as activators of NKT cells. The compositions and methods of the present invention are useful for the prevention and treatment of diseases.
Type:
Grant
Filed:
June 3, 2016
Date of Patent:
October 30, 2018
Assignees:
Vaccinex, Inc., Albert Einstein College of Medicine, Inc.